BRISTOL-MYERS SQUIBB COMPANY (BMY) 2025 Earnings Analysis
BRISTOL-MYERS SQUIBB COMPANY2025 Earnings Analysis
70/100
Bristol-Myers Squibb's FY2025 delivers a pharma franchise in renewed growth mode: $48.2B revenue (flat YoY but $34.3B gross profit at 71.1% margin), $7.1B net income, and $12.8B FCF. The growth portfolio — Opdivo, Eliquis, Reblozyl, Camzyos, and new oncology platforms including ADCs, CAR-T, and radiopharmaceuticals — is offsetting legacy product LOE erosion. The 38.2% ROE signals efficient capital deployment, but $44.8B long-term debt (79.5% debt ratio) from the Celgene acquisition legacy constrains balance sheet flexibility. The moat hinges on pipeline execution across next-generation oncology and immunology platforms.
Core Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Earnings Quality
Gross margin of 71.1% on $48.2B revenue ($34.3B gross profit) reflects BMS's specialty pharma pricing power across oncology, hematology, immunology, and cardiovascular therapeutics. The 10-K describes BMS as operating 'in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines.'
Operating cash flow of $14.2B versus $7.1B net income yields a 2.01x ratio. The premium reflects non-cash amortization of acquired intangibles from the $74B Celgene acquisition. Like AbbVie, GAAP net income underrepresents BMS's cash earning power due to acquisition-related charges.
FCF of $12.8B ($14.2B OCF minus $1.3B capex) represents a 26.6% FCF margin on $48.2B revenue. The minimal 2.7% capex/revenue ratio is typical for biopharmaceuticals and enables virtually all operating cash flow to convert to distributable free cash flow.
Goodwill of $21.8B (24.2% of $90.0B total assets) primarily from the Celgene acquisition. This significant balance carries impairment risk, though the successful performance of acquired assets (Revlimid legacy, Reblozyl, Breyanzi CAR-T) provides support.
Earnings quality scores 82/100 — strong pharma cash generation with Celgene-related GAAP distortion. The 71.1% gross margin and $12.8B FCF demonstrate genuine earning power. The 2.01x CF/NI ratio flags that Celgene intangible amortization depresses GAAP earnings, but the cash flow is real and substantial. Revenue flat at $48.2B ($48.3B in FY2024) as growth products offset legacy erosion — a critical inflection that needs to turn positive.
Moat Strength
The 10-K describes platforms spanning 'chemically-synthesized or small molecule drugs including protein degraders, biologics, ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics.' Opdivo (nivolumab) is the anchor immuno-oncology franchise. This multi-modality approach creates a broad patent portfolio that is difficult for any single competitor to replicate.
A 71.1% gross margin reflects strong pricing power across BMS's specialty portfolio. The 10-K shows revenue split approximately 69% U.S., 29% International, 2% Other — U.S. concentration supports premium pricing in the world's largest pharmaceutical market.
BMS's 10-K describes acquisitions including Orbital Therapeutics, a strategic collaboration with BioNTech, and a licensing agreement with Philochem in 2025. The focus on 'oncology, hematology, immunology, cardiovascular, neuroscience' creates multiple shots on goal for revenue replacement as key products face patent expiry.
Several key BMS products face loss of exclusivity in the coming years, including Eliquis (one of the world's best-selling drugs). The 10-K's flat revenue ($48.2B vs $48.3B YoY) reflects the tension between growth portfolio expansion and legacy product erosion. Successful execution of the growth portfolio pipeline is essential to offset LOE headwinds.
Moat strength scores 76/100 — a pharma moat in active transition. BMS's multi-modality oncology platforms (small molecules, biologics, ADCs, CAR-T, radiopharmaceuticals) create a diversified competitive advantage, and the 71.1% gross margin confirms pricing power. However, the flat revenue ($48.2B) signals the moat is being tested by LOE erosion. The 2025 acquisitions (Orbital) and partnerships (BioNTech, Philochem) demonstrate management's urgency in pipeline renewal.
Capital Allocation
ROE of 38.2% on $18.5B equity reflects efficient capital deployment in a high-margin biopharmaceutical franchise. This strong ROE is partially enhanced by leverage (79.5% debt ratio) but also reflects genuine earning power — $7.1B net income on a moderate equity base.
Long-term debt of $44.8B represents the Celgene acquisition legacy. The 79.5% debt ratio constrains strategic flexibility, though $12.8B annual FCF provides comfortable debt servicing capacity. Deleveraging progress is critical to restoring balance sheet flexibility for future pipeline acquisitions.
FCF of $12.8B at 26.6% margin provides the foundation for dividends, debt reduction, and pipeline investment. The priority allocation challenge: service $44.8B debt, fund R&D pipeline, maintain dividends, and pursue business development — all competing for the same $12.8B cash pool.
Capital allocation scores 68/100 — strong cash generation constrained by Celgene debt legacy. The 38.2% ROE and $12.8B FCF demonstrate capital efficiency, but $44.8B in long-term debt limits strategic options. BMS must simultaneously deleverage, invest in pipeline (Orbital acquisition, BioNTech partnership), and maintain dividends — a challenging capital allocation juggling act.
Key Risks
Eliquis is one of the world's best-selling drugs and faces upcoming loss of exclusivity. The revenue replacement challenge is enormous — BMS must have growth products ready to absorb potentially billions in Eliquis revenue erosion from generic competition.
BMS's revenue sustainability depends on successfully developing and commercializing next-generation platforms including protein degraders, ADCs, CAR-T therapies, and radiopharmaceuticals. Clinical trial failures, regulatory setbacks, or competitive entries could derail the growth thesis.
The 79.5% debt ratio with $44.8B long-term debt limits BMS's ability to pursue transformative acquisitions. In a pharma industry where pipeline replenishment often requires M&A, this debt burden is a competitive disadvantage relative to less-leveraged peers.
With 69% of revenue from the U.S., BMS is heavily exposed to U.S. drug pricing reforms, IRA negotiation provisions, and payer dynamics. Any expansion of Medicare drug price negotiation or Medicaid rebate requirements could materially impact revenue and margins.
Risk profile scores 52/100 (higher = safer). The Eliquis LOE is the single biggest risk — losing this blockbuster's revenue without adequate replacement products would structurally impair BMS. Pipeline execution risk across multiple modalities (ADCs, CAR-T, radiopharmaceuticals) adds uncertainty. The 79.5% debt ratio constrains strategic flexibility, and 69% U.S. revenue concentration exposes BMS to drug pricing reforms.
Management
Ask about this section
This analysis is for educational purposes only and does not constitute investment advice.